Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
Acral melanoma
Anti-PD-L1 antibody
Immunohistochemistry
Melanoma
Mucosal melanoma
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
17
11
2021
accepted:
06
05
2022
pubmed:
2
6
2022
medline:
27
7
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
The immunohistochemical evaluation of programmed death ligand 1 (PD-L1) is important for selecting treatments. Several antibodies are available for such evaluations, but data regarding the differences in the antibodies' positivity are limited in melanoma, particularly the acral and mucosal types. We investigated the differences in melanoma tissues' PD-L1 expression among the commonly used PD-L1 antibodies and then evaluated the relationship between PD-L1+ tumor cells and tumor-infiltrating lymphocytes (TILs). We examined 56 primary lesions and 8 metastatic lymph node samples from 56 Japanese patients with melanoma (28 acral melanoma, 8 mucosal melanoma, 18 cutaneous melanoma, 2 unknown). Immunohistochemical staining was performed using three primary antibodies against PD-L1 (E1L3N, SP142, and 28-8). PD-L1-positive staining in tumor cells was defined as ≥ 1% expression. The positive rates were 25.0% for 28-8, 34.0% for E1L3N, and 34.0% for SP142 in 64 samples. The positive rates of acral melanoma were 10.7% for 28-8, 21.4% for E1L3N, and 21.4% for SP142. The positive rate of mucosal melanoma for which all three antibodies reacted was 12.5%. The positive rates of cutaneous melanoma were 55.6% for 28-8, 66.7% for E1L3N, and 66.7% for SP142. Significant relationships were observed among the PD-L1+ tumor cells, CD4+ TILs, and CD8+ TILs (p < 0.001). The staining results by E1L3N, SP142, and 28-8 antibodies were within the allowable range, although the positive rates by E1L3N and P142 were slightly higher than that of 28-8. CD4+ TILs and CD8+ TILs were quantitatively correlated with PD-L1-positive tumor cells.
Sections du résumé
BACKGROUND
BACKGROUND
The immunohistochemical evaluation of programmed death ligand 1 (PD-L1) is important for selecting treatments. Several antibodies are available for such evaluations, but data regarding the differences in the antibodies' positivity are limited in melanoma, particularly the acral and mucosal types. We investigated the differences in melanoma tissues' PD-L1 expression among the commonly used PD-L1 antibodies and then evaluated the relationship between PD-L1+ tumor cells and tumor-infiltrating lymphocytes (TILs).
PATIENTS AND METHODS
METHODS
We examined 56 primary lesions and 8 metastatic lymph node samples from 56 Japanese patients with melanoma (28 acral melanoma, 8 mucosal melanoma, 18 cutaneous melanoma, 2 unknown). Immunohistochemical staining was performed using three primary antibodies against PD-L1 (E1L3N, SP142, and 28-8). PD-L1-positive staining in tumor cells was defined as ≥ 1% expression.
RESULTS
RESULTS
The positive rates were 25.0% for 28-8, 34.0% for E1L3N, and 34.0% for SP142 in 64 samples. The positive rates of acral melanoma were 10.7% for 28-8, 21.4% for E1L3N, and 21.4% for SP142. The positive rate of mucosal melanoma for which all three antibodies reacted was 12.5%. The positive rates of cutaneous melanoma were 55.6% for 28-8, 66.7% for E1L3N, and 66.7% for SP142. Significant relationships were observed among the PD-L1+ tumor cells, CD4+ TILs, and CD8+ TILs (p < 0.001).
CONCLUSION
CONCLUSIONS
The staining results by E1L3N, SP142, and 28-8 antibodies were within the allowable range, although the positive rates by E1L3N and P142 were slightly higher than that of 28-8. CD4+ TILs and CD8+ TILs were quantitatively correlated with PD-L1-positive tumor cells.
Identifiants
pubmed: 35650364
doi: 10.1007/s10147-022-02189-7
pii: 10.1007/s10147-022-02189-7
doi:
Substances chimiques
Antibodies
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1364-1371Informations de copyright
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Madore J, Vilain RE, Menzies AM et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28:245–253. https://doi.org/10.1111/pcmr.12340
doi: 10.1111/pcmr.12340
pubmed: 25477049
Gandini S, Massi D, Mandalà M (2016) PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88–98. https://doi.org/10.1016/j.critrevonc.2016.02.001
doi: 10.1016/j.critrevonc.2016.02.001
pubmed: 26895815
Frydenlund N, Mahalingam M (2017) PD-L1 and immune escape: Insights from melanoma and other lineage-unrelated malignancies. Hum Pathol 66:13–33. https://doi.org/10.1016/j.humpath.2017.06.012
doi: 10.1016/j.humpath.2017.06.012
pubmed: 28694003
Wang Q, Liu F, Liu L (2017) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore) 96(18):e6369. https://doi.org/10.1097/md.0000000000006369
doi: 10.1097/md.0000000000006369
Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7:4231. https://doi.org/10.1038/s41598-017-04023-x
doi: 10.1038/s41598-017-04023-x
pubmed: 28652622
pmcid: 5484664
Wu P, Wu D, Li L et al (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 10:e0131403. https://doi.org/10.1371/journal.pone.0131403
doi: 10.1371/journal.pone.0131403
pubmed: 26114883
pmcid: 4483169
Li X, Li M, Lian Z et al (2016) Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol 11:753–761. https://doi.org/10.1007/s11523-016-0451-8
doi: 10.1007/s11523-016-0451-8
pubmed: 27422273
Sun JM, Zhou W, Choi YL et al (2016) Prognostic significance of PD-l1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11:1003–1011. https://doi.org/10.1016/j.jtho.2016.04.007
doi: 10.1016/j.jtho.2016.04.007
pubmed: 27103510
Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222. https://doi.org/10.1016/j.jtho.2016.11.2228
doi: 10.1016/j.jtho.2016.11.2228
pubmed: 27913228
Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013
doi: 10.1016/j.jtho.2018.05.013
pubmed: 29800747
pmcid: 8386299
Sunshine JC, Nguyen PL, Kaunitz GJ et al (2017) PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res 23:4938–4944. https://doi.org/10.1158/1078-0432.CCR-16-1821
doi: 10.1158/1078-0432.CCR-16-1821
pubmed: 28428193
pmcid: 6175606
Fujisawa Y, Yoshikawa S, Minagawa A et al (2019) Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 8:2146–2156. https://doi.org/10.1002/cam4.2110
doi: 10.1002/cam4.2110
pubmed: 30932370
pmcid: 6536943
Saglam O, Zhou J, Wang X et al (2020) PD-L1 expression correlates with young age and CD8+ TIL density in poorly differentiated cervical squamous cell carcinoma. Int J Gynecol Pathol 39:428–435. https://doi.org/10.1097/pgp.0000000000000623
doi: 10.1097/pgp.0000000000000623
pubmed: 31274701
pmcid: 7010346
Yun S, Park Y, Moon S et al (2019) Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer 10:3070–3078. https://doi.org/10.7150/jca.30573
doi: 10.7150/jca.30573
pubmed: 31281485
pmcid: 6590033
Farhood B, Najafi M, Mortezaee K (2019) CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509–8521. https://doi.org/10.1002/jcp.27782
doi: 10.1002/jcp.27782
pubmed: 30520029
Frydenlund N, Leone D, Yang S et al (2017) Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod Pathol 30:357–369. https://doi.org/10.1038/modpathol.2016.210
doi: 10.1038/modpathol.2016.210
pubmed: 28084337
Tsukamoto H, Fujieda K, Miyashita A et al (2018) Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res 78:5011–5022. https://doi.org/10.1158/0008-5472.Can-18-0118
doi: 10.1158/0008-5472.Can-18-0118
pubmed: 29967259
Nakamura Y, Ishitsuka Y, Tanaka R et al (2019) Acral lentiginous melanoma and mucosal melanoma expressed less programmed-death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients. J Eur Acad Dermatol Venereol 33:e424–e426. https://doi.org/10.1111/jdv.15742
doi: 10.1111/jdv.15742
pubmed: 31187906
Nakamura Y, Namikawa K, Yoshino K et al (2020) Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol 31:1198–1206. https://doi.org/10.1016/j.annonc.2020.05.031
doi: 10.1016/j.annonc.2020.05.031
pubmed: 32522691
D’Angelo SP, Larkin J, Sosman JA et al (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35:226–235. https://doi.org/10.1200/jco.2016.67.9258
doi: 10.1200/jco.2016.67.9258
pubmed: 28056206
Shoushtari AN, Munhoz RR, Kuk D et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122:3354–3362. https://doi.org/10.1002/cncr.30259
doi: 10.1002/cncr.30259
pubmed: 27533633
Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN et al (2020) Nodular primary cutaneous melanoma is associated with PD-L1 expression. Eur J Dermatol 30:352–357. https://doi.org/10.1684/ejd.2020.3846
doi: 10.1684/ejd.2020.3846
pubmed: 32969795
Thangarajah F, Morgenstern B, Pahmeyer C et al (2019) Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. J Cancer Res Clin Oncol 145:1651–1660. https://doi.org/10.1007/s00432-019-02915-1
doi: 10.1007/s00432-019-02915-1
pubmed: 30972492
Kato J, Sugita S, Horimoto K et al (2021) Expression of programmed cell death ligand 1 (PD-L1) at in situ and invasive extramammary Paget’s disease and literature review. Australas J Dermatol 62:412–414. https://doi.org/10.1111/ajd.13607
doi: 10.1111/ajd.13607
pubmed: 33979450
Gu L, Chen M, Guo D et al (2017) PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One 12:e0182692. https://doi.org/10.1371/journal.pone.0182692
doi: 10.1371/journal.pone.0182692
pubmed: 28796808
pmcid: 5552131
Rozenblit M, Huang R, Danziger N et al (2020) Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer 8:e001558. https://doi.org/10.1136/jitc-2020-001558
doi: 10.1136/jitc-2020-001558
pubmed: 33239417
pmcid: 7689582
Blank CU, Rozeman EA, Fanchi LF et al (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24:1655–1661. https://doi.org/10.1038/s41591-018-0198-0
doi: 10.1038/s41591-018-0198-0
pubmed: 30297911